{"id":"https://openalex.org/W2594669079","doi":"https://doi.org/10.1111/ejh.12877","title":"Carfilzomib\u2010containing combinations as frontline therapy for multiple myeloma: A meta\u2010analysis of 13 trials","display_name":"Carfilzomib\u2010containing combinations as frontline therapy for multiple myeloma: A meta\u2010analysis of 13 trials","publication_year":2017,"publication_date":"2017-03-12","ids":{"openalex":"https://openalex.org/W2594669079","doi":"https://doi.org/10.1111/ejh.12877","mag":"2594669079","pmid":"https://pubmed.ncbi.nlm.nih.gov/28295593"},"language":"en","primary_location":{"id":"doi:10.1111/ejh.12877","doi":"https://doi.org/10.1111/ejh.12877","is_oa":false,"landing_page_url":"https://doi.org/10.1111/ejh.12877","pdf_url":null,"source":{"id":"https://openalex.org/S159715054","display_name":"European Journal Of Haematology","issn_l":"0902-4441","issn":["0902-4441","1600-0609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Haematology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084770797","display_name":"Zhixin Sheng","orcid":"https://orcid.org/0000-0001-9986-7875","observed_orcids":["https://orcid.org/0000-0001-9986-7875"]},"institutions":[{"id":"https://openalex.org/I4210113011","display_name":"Weifang People's Hospital","ror":"https://ror.org/01xd2tj29","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210113011"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhixin Sheng","raw_affiliation_strings":["Department of Hematology, Weifang People's Hospital, Weifang, China"],"raw_orcid":"https://orcid.org/0000-0001-9986-7875","affiliations":[{"raw_affiliation_string":"Department of Hematology, Weifang People's Hospital, Weifang, China","institution_ids":["https://openalex.org/I4210113011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100747707","display_name":"Guifang Li","orcid":"https://orcid.org/0009-0009-1537-6274","observed_orcids":["https://orcid.org/0009-0009-1537-6274","https://orcid.org/0000-0002-4751-5402"]},"institutions":[{"id":"https://openalex.org/I4210113011","display_name":"Weifang People's Hospital","ror":"https://ror.org/01xd2tj29","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210113011"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Guifang Li","raw_affiliation_strings":["Department of Occupational Disease, Weifang People's Hospital, Weifang, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Occupational Disease, Weifang People's Hospital, Weifang, China","institution_ids":["https://openalex.org/I4210113011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100365175","display_name":"Bin Li","orcid":"https://orcid.org/0000-0002-3769-7476","observed_orcids":["https://orcid.org/0000-0002-3769-7476"]},"institutions":[{"id":"https://openalex.org/I4210113011","display_name":"Weifang People's Hospital","ror":"https://ror.org/01xd2tj29","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210113011"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Bin Li","raw_affiliation_strings":["Department of Respiration, Weifang People's Hospital, Weifang, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Respiration, Weifang People's Hospital, Weifang, China","institution_ids":["https://openalex.org/I4210113011"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yanju Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210113011","display_name":"Weifang People's Hospital","ror":"https://ror.org/01xd2tj29","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210113011"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yanju Liu","raw_affiliation_strings":["Department of Infection, Weifang People's Hospital, Weifang, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Infection, Weifang People's Hospital, Weifang, China","institution_ids":["https://openalex.org/I4210113011"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004638853","display_name":"Lida Wang","orcid":"https://orcid.org/0000-0002-8363-3350","observed_orcids":["https://orcid.org/0000-0002-8363-3350","https://orcid.org/0009-0004-0098-7981"]},"institutions":[{"id":"https://openalex.org/I4210113011","display_name":"Weifang People's Hospital","ror":"https://ror.org/01xd2tj29","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210113011"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Lida Wang","raw_affiliation_strings":["E.N.T. department, Weifang People's Hospital, Weifang, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"E.N.T. department, Weifang People's Hospital, Weifang, China","institution_ids":["https://openalex.org/I4210113011"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5004638853"],"corresponding_institution_ids":["https://openalex.org/I4210113011"],"apc_list":{"value":4650,"currency":"USD","value_usd":4650},"apc_paid":null,"fwci":1.2392,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.79638596,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":97},"biblio":{"volume":"98","issue":"6","first_page":"601","last_page":"607"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/carfilzomib","display_name":"carfilzomib","score":1.0},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.968999981880188},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.9010000228881836},{"id":"https://openalex.org/keywords/newly-diagnosed-multiple-myeloma","display_name":"newly diagnosed multiple myeloma","score":0.9629999995231628},{"id":"https://openalex.org/keywords/lenalidomide","display_name":"lenalidomide","score":0.871999979019165},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.8989999890327454},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.8519999980926514},{"id":"https://openalex.org/keywords/thiotepa","display_name":"thiotepa","score":0.8370000123977661},{"id":"https://openalex.org/keywords/autologous-stem-cell-transplantation","display_name":"autologous stem cell transplantation","score":0.7870000004768372},{"id":"https://openalex.org/keywords/consolidation-therapy","display_name":"consolidation therapy","score":0.9599999785423279},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.7229999899864197},{"id":"https://openalex.org/keywords/very-good-partial-response","display_name":"very good partial response","score":0.8029999732971191},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.3790000081062317},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6240000128746033}],"concepts":[{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.9908747673034668},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.7841525077819824},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7707429528236389},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.6693304181098938},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5372720956802368},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4827422499656677},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.38729265332221985},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.3566451072692871}],"mesh":[{"descriptor_ui":"D000077269","descriptor_name":"Lenalidomide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D013792","descriptor_name":"Thalidomide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014184","descriptor_name":"Transplantation, Homologous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D033581","descriptor_name":"Stem Cell Transplantation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/ejh.12877","doi":"https://doi.org/10.1111/ejh.12877","is_oa":false,"landing_page_url":"https://doi.org/10.1111/ejh.12877","pdf_url":null,"source":{"id":"https://openalex.org/S159715054","display_name":"European Journal Of Haematology","issn_l":"0902-4441","issn":["0902-4441","1600-0609"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Haematology","raw_type":"journal-article"},{"id":"pmid:28295593","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28295593","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of haematology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":21,"referenced_works":["https://openalex.org/W2646510","https://openalex.org/W1706760553","https://openalex.org/W1973621728","https://openalex.org/W1985864219","https://openalex.org/W1986036865","https://openalex.org/W2016742872","https://openalex.org/W2050465851","https://openalex.org/W2074812363","https://openalex.org/W2090310344","https://openalex.org/W2093665884","https://openalex.org/W2120362266","https://openalex.org/W2126267349","https://openalex.org/W2140579395","https://openalex.org/W2508496893","https://openalex.org/W2513834994","https://openalex.org/W2528151402","https://openalex.org/W2575252632","https://openalex.org/W2594118066","https://openalex.org/W2606148909","https://openalex.org/W2979804295","https://openalex.org/W4229965854"],"related_works":["https://openalex.org/W2768999098","https://openalex.org/W7124451715","https://openalex.org/W4389230230","https://openalex.org/W2606014967","https://openalex.org/W2891730833","https://openalex.org/W3203061905","https://openalex.org/W1969524425","https://openalex.org/W4417069324","https://openalex.org/W2985631013","https://openalex.org/W2962995528"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"investigate":[2],"the":[3,187],"activity":[4],"and":[5,86,148,180],"safety":[6],"of":[7,56,66,72,77,84,88,105,119,134,183,189],"carfilzomib-containing":[8],"combinations":[9,40,157],"as":[10,41],"frontline":[11,42],"therapy":[12,43],"for":[13,22,44],"multiple":[14,25,45,167],"myeloma.":[15,26,168],"METHODS:":[16],"We":[17],"searched":[18],"published":[19],"carfilzomib":[20,39,95],"reports":[21],"newly":[23,163],"diagnosed":[24,164],"RESULTS:":[27],"Thirteen":[28],"trials":[29],"were":[30,80,140],"identified,":[31],"covering":[32],"704":[33],"subjects.":[34],"Pooled":[35],"analysis":[36],"showed":[37],"that":[38],"myeloma":[46],"attained":[47],"an":[48],"impressive":[49],"at":[50,58],"least":[51,59],"complete":[52],"response":[53,63,69,97,170],"(\u2265CR)":[54],"rate":[55,65,70,171],"21%,":[57],"very":[60],"good":[61,195],"partial":[62],"(\u2265VGPR)":[64],"68%,":[67],"overall":[68],"(ORR)":[71],"94%.":[73],"The":[74],"\u2265CR":[75,132],"rates":[76,104,133],"18%":[78,143],"pre-SCT":[79],"increased":[81],"to":[82],"43%":[83,114],"post-ASCT,":[85],"64%":[87],"postconsolidation":[89],"(P<.001).":[90],"For":[91],"those":[92],"patients":[93,165],"receiving":[94],"therapy,":[96,179],"quality":[98],"improved":[99,175],"further":[100,174],"over":[101],"time":[102],"(\u2265CR":[103],"10%":[106],"after":[107,111,115,121,125,129],"2nd":[108,122],"cycle,":[109,113,123,127],"20%":[110],"4th":[112,126],"8th":[116,130],"cycle;":[117],"\u2265VGPR":[118],"29%":[120],"68%":[124],"88%":[128],"cycle).":[131],"49%":[135],"from":[136,144,150],"CFZ-LEN-DEX":[137,191],"triplet":[138,146,152],"regimen":[139,147,153],"higher":[141],"than":[142],"CFZ-CYC-DEX":[145],"21%":[149],"CFZ-THA-DEX":[151],"(P=.03).":[154],"CONCLUSIONS:":[155],"Carfilzomib":[156],"could":[158,172,192],"produce":[159],"clinical":[160],"benefits":[161],"in":[162,186],"with":[166],"High-quality":[169],"be":[173,193],"through":[176],"ASCT,":[177],"consolidation":[178],"more":[181],"cycles":[182],"chemotherapy":[184],"even":[185],"era":[188],"carfilzomib.":[190],"a":[194],"combination":[196],"regimen.":[197]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-03-16T00:00:00"}